|
APC | Adenomatosis polyposis coli |
BRCA1 | Breast cancer 1, early onset |
BRCA2 | Breast cancer 2, early onset |
CBP | Human CREB-binding protein |
DPC4 | Human homozygous deletion target in pancreatic carcinoma (DPC4) |
IRF-1 | Interferon regulatory factor 1 |
MSH2 | mutS (E. coli) homolog 2 (colon cancer, nonpolyposis type 1) |
NF2 | Neurofibromin 2 (bilateral acoustic neuroma) |
p18 (cdk4 inhibitor) | Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
p19Ink4d | Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) |
p21Waf1 (p21Cip1) | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
p27Kip1 | Cyclin-dependent kinase inhibitor 1B (p27, Kip1) |
p300 | CREB-binding protein |
p53 | Tumor protein p53 (Li-Fraumeni syndrome) |
p57Kip2 | Cyclin-dependent kinase inhibitor 1C (p57, Kip2) |
PTEN | Phosphatase and tensin homolog (mutated in multiple advanced cancers 1 |
Rb | Retinoblastoma 1 (including osteosarcoma) |
TGFbR1 (ALK-5) | Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kD) |
TGFbR2 | Transforming growth factor, beta receptor II (70–80 kD) |
TSC-1 | Tuberous sclerosis 1 |
TSC-2 | Tuberous sclerosis 2 |
VHL | Von Hippel-Lindau syndrome |
WT1 | Wilms tumor 1 |
|